Needham & Company LLC Reaffirms "Buy" Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at Needham & Company LLC in a report issued on Thursday,Benzinga reports. They presently have a $207.00 target price on the specialty pharmaceutical company's stock. Needham & Company LLC's price target would indicate a potential upside of 67.48% from the stock's current price.

JAZZ has been the subject of several other research reports. Royal Bank of Canada reiterated an "outperform" rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday. HC Wainwright reiterated a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an "overweight" rating in a research report on Monday, August 19th. TD Cowen cut their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating on the stock in a report on Thursday, November 7th. Finally, Robert W. Baird increased their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research note on Monday, November 18th. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $177.00.

Jazz Pharmaceuticals Stock Up 2.4 %

Shares of NASDAQ:JAZZ traded up $2.88 during trading on Thursday, reaching $123.60. 749,072 shares of the stock were exchanged, compared to its average volume of 667,773. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $134.17. The stock has a fifty day moving average of $116.81 and a two-hundred day moving average of $111.91. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market cap of $7.47 billion, a price-to-earnings ratio of 17.63, a price-to-earnings-growth ratio of 1.04 and a beta of 0.57.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $121.17, for a total value of $242,340.00. Following the sale, the chief executive officer now owns 427,025 shares in the company, valued at $51,742,619.25. This represents a 0.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,753 shares of company stock worth $816,289. 4.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Itau Unibanco Holding S.A. purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $29,000. EverSource Wealth Advisors LLC lifted its position in Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. Gladius Capital Management LP purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at $33,000. GAMMA Investing LLC increased its holdings in shares of Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company's stock worth $46,000 after purchasing an additional 121 shares in the last quarter. Finally, Venturi Wealth Management LLC raised its stake in shares of Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company's stock worth $92,000 after purchasing an additional 704 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.